Mingyi Zhudao Secures RMB 150 Million Series B Funding; Proteus Digital Health Raises $50 Million for Smart Pill Technology

April 18 to April 24,Total Financing Inflows in the Domestic and International Digital Health Sectors Exceeded$400 million.

It is reported that the highlight of domestic investment and financing activities this week was Mingyi Zhudao’s announcement of the completion of its RMB 150 million Series B financing round, with ZhenFund participating in the investment. Meanwhile, abroad, Proteus Digital Health secured $50 million in Series H financing for its smart chip pill.

First, let’s focus on the domestic market. This week, the most prominent investment and financing event in China was led by Mingyi Zhudao. Aiming to become the “Uber” of mobile healthcare, Mingyi Zhudao makes it easier for patients requiring surgery to choose their surgeons, sparing them the hassle of struggling to secure appointments with renowned specialists. Below, we will provide a detailed overview of the key domestic investment and financing highlights, headlined by Mingyi Zhudao.

Analysis of Hot Investment and Financing Projects in China



This Week's Hot Fundraising Project: Mingyi Zhudao

• Performed by Renowned Experts —Building the Uber of Mobile Healthcare

Mingyi Zhudao was established in October 2014 as a mobile medical surgery platform focused on surgical management. It aims to provide professional and efficient surgical medical services to patients across China through an innovative model. The platform aggregates resources of physicians and hospital beds, leveraging internet technology to achieve precise matching between doctors and patients, thereby helping patients secure appointments with specialists for surgical treatment at the earliest opportunity. This platform enables renowned medical experts from across China to utilize their spare time, after fulfilling their mandated duties at public hospitals, to serve a broader patient population. The company aims to become the "Uber" of the mobile healthcare sector.On July 31, 2015, Mingyi Zhudao secured RMB 5 million in angel-round financing led by ZhenFund. Subsequently, on October 26, 2015, it obtained RMB 60 million in Series A financing from Fosun Pharma, Gaorong Capital, and ZhenFund. On April 20, 2016, the company raised RMB 150 million in Series B financing, led by Hanfu Capital and Yueyin Ventures, with participation from Fosun Pharma, Gaorong Capital, and ZhenFund.It is reported that Mingyi Zhudao has launched the "Sharing Renowned Medical Resources, Building a Healthy China Together" charitable surgery donation project. This initiative aims to improve medical standards in small and medium-sized cities, underdeveloped western regions, and rural areas by providing free high-end expert medical volunteer services to underserved populations, thereby enhancing the overall level and quality of medical services in less developed regions.

Mingyi Zhudao not only provides ordinary people with a platform to schedule surgeries with renowned specialists, but also contributes to public welfare in healthcare. The platform leverages internet resources,Attract a large number of high-end medical professionals to join as volunteers，It provides a conceptual framework and practical solutions for gradually addressing the uneven distribution of medical resources and difficulties in accessing healthcare in China.Such a socialA socially responsible and caring startup—we give them a thumbs-up!

On one side, a renowned physician performs the surgery$150 million in financing; meanwhile, another company is also highly sought after, securing RMB 185 million in its Series B round. Let’s take a closer look at the details of this company.

• Shanghai Cell Therapy Engineering Technology Research Center——Integrated Production, Treatment, and R&DAll-around Company

Established in November 2013, the Shanghai Cell Therapy Engineering Technology Research Center is a municipal-level engineering technology research center approved by the Shanghai Municipal Science and Technology Commission. The company positions itself as a full-industry-chain R&D institution and therapeutic platform in the field of cell therapy, with business operations encompassing cell therapy, cell cryopreservation, genetic testing, and medical big data. The medical big database under construction will become China’s largest internet platform for cancer treatment, supporting the data needs of healthcare professionals and patients, as well as providing popular science education and a professional knowledge base for oncology. On April 21, 2016, Shanghai Cell Therapy Group secured RMB 185 million in Series B financing, bringing its post-money valuation to RMB 835 million. The investors in this round were Legend Capital and Yaoji Poker.

What? Yaoji Poker! You heard it right, folks—it’s Yaoji Poker, the playing card manufacturer. Anyone who enjoys card games is surely very familiar with this name. The company is no longer just focused on entertainment; it has expanded into the broader health and wellness sector. In 2014, Yaoji Poker established its “Big Entertainment + Big Health” strategic plan. Indeed, Yaoji Poker has made a significant leap across industries. This shows that to achieve growth, we must broaden our horizons and explore new fields, where unexpected opportunities may await.



The Shanghai Cell Therapy Engineering Technology Research Center boasts first-class technical expertise. However, another company also leverages R&D as its core productive force; the two are closely matched, making it difficult to distinguish a clear leader.

• Hua Medicine –“Integration of Chinese and Western Medicine, Collaborative Innovation”

Hua Medicine was established in June 2011 as an innovative drug research and development company, focusing on the R&D and industrialization of novel therapies and products for the treatment of diabetes and central nervous system disorders. The company was co-founded by experienced entrepreneurs in the biopharmaceutical sector and renowned investment institutions. Hua Medicine’s strategy leverages its in-house drug R&D and management capabilities to introduce overseas technologies and product resources, adopting a “East-meets-West, collaborative innovation” operational model to develop, manufacture, and market innovative products and services in the field of major diseases. The company is committed to becoming a significant driving force in China’s advancement toward becoming a global hub for drug R&D and innovation. On April 22, 2016, Hua Medicine, which specializes in innovative drug R&D, announced the completion of a USD 50 million Series C financing round in both US dollars and Renminbi. The round was led by Harvest Investment, with Tonghe Capital participating as a co-investor, and China Renaissance served as the exclusive financial advisor. The proceeds from this financing will be used to complete Phase II clinical trials of HMS5552, an innovative fourth-generation glucokinase activator for the treatment of type 2 diabetes, and to accelerate its entry into Phase III clinical studies. The funds will also support the development of other new drug candidates and technology projects.

Hua Medicine has actively introduced overseas technologies and product resources, producing and marketing products and services for major diseases in light of its own circumstances. The integration of Chinese characteristics with Western approaches is truly commendable. Speaking of the introduction of foreign specialties, those following the healthcare sector must have heard of Sanpower Group,In December 2014, Sanpower Group acquired Natali Seculife Holding Ltd., Israel’s largest home healthcare service provider., achieving a true integration of Chinese and Western medicine. Recently, Sanpower Group has made new moves.

• Sanpower Group – Establishing a tripartite health ecosystem integrating healthy elderly care, biomedicine, and hospital management

Recently, Sanpower Group announced that its subsidiary, Sanpower International Healthcare Management Co., Ltd., and Shanghai Benyu Investment Management Co., Ltd. have jointly established the Sanpower-Benyu Health Industry Fund, with a total size of RMB 10 billion. On June 15, 2015, Sanpower International Healthcare Management Co., Ltd., under Sanpower Group, signed a strategic cooperation agreement with Shanghai Yinlai Equity Investment Fund Management Co., Ltd. at Sanpower Group’s headquarters to jointly initiate the Sanpower-Yinlai Medical Investment Fund, with a fund size of RMB 5 billion. On September 16, 2015, Nanjing Xinjiekou Department Store Co., Ltd. (“Nanjing Xinbai”), controlled by Sanpower Group, stated its intention to partner with Shanghai Chuangxin and Shanghai Kangcheng to jointly initiate a limited partnership equity investment fund focused on investments in the broader health sector, tentatively named the “Xinbai Innovation Health Investment Fund,” with a fund size of RMB 5 billion. It is reported that the Sanpower-Benyu Health Industry Fund is the largest health industry fund established under Sanpower Group. The fund focuses on investing in medical services, pharmaceutical products, healthcare products, nutritional foods, medical devices, health appliances, leisure and fitness, health management, and health consulting, with key investment regions being first- and second-tier cities in China as well as areas with unique resource advantages.

Sanpower Group has established three funds in the healthcare sector, demonstrating its considerable corporate resources and financial strength.

Having reviewed the key investment and financing events in China, let us now turn our attention to the global healthcare sector and examine the noteworthy investment and financing activities that occurred abroad this week.



Analysis of Hot Investment Projects Abroad



An Exceptionally Creative Project

• Proteus Digital Health—Developer of Smart Chip Pills

Proteus Digital Health, founded in 2001 and headquartered in California, USA, is dedicated to developing digital health products that collect various human metrics related to behavior, physiology, and treatment—including medication adherence, heart rate, sleep patterns, physical activity, and stress levels—with the aim of providing consumers with personalized health management tools. After a patient ingests the pill, it reaches the stomach, where electrodes within the pill’s sensor draw power from gastric acid and transmit signals outward. This smart chip-enabled pill received FDA clearance in July 2012. Recently, the company announced the completion of a $50 million Series H financing round, bringing the total funding raised for the project to $350 million.

No need to doubt; it is indeed true.Edible Chips! Implanting a tiny chip in the body to monitor various physiological metrics—once a capability reserved for superheroes in sci-fi movies—has now become accessible to the general public.



Hmm, if a person carrying specific pathogenic genes for major diseases ingests this chip, can the chip detect the presence of such pathogenic genes? The following project focuses on precision therapy for patients with specific cardiovascular pathogenic genes.

·DalCor Pharmaceuticals— Dedicated to the field of cardiovascular diseases driven by rare pathogenic genes

DalCor Pharmaceuticals (hereinafter referred to as “DalCor”) is a startup company dedicated to advancing precision medicine for cardiovascular diseases. The drug under development by DalCor, dalcetrapib, is a cholesteryl ester transfer protein (CETP) inhibitor. By modulating CETP activity, dalcetrapib can increase levels of functional high-density lipoprotein (HDL), thereby reducing the risk of cardiovascular disease. This medication is designed for targeted therapy in cardiovascular disease patients with specific genetic profiles. Recently, the company secured $100 million in Series B financing. Following the completion of this round, DalCor announced that it had achieved its total fundraising target of $150 million and stated that the funds would be used to conduct Phase III clinical trials of dalcetrapib.

Preventing cardiovascular diseases caused by specific pathogenic genes before they occur, achieving the goal of "preventive treatment."DalCor's R&D capabilities are indeed impressive.

That’s all for this week’s investment and financing weekly report. See you next Monday. Thank you very much for watching, everyone. Let’s kick off the new week with full energy!

For the latest and hottest funding news in the domestic and international internet healthcare sector, please continue to follow VCBeat.。